Clinical Trial

Effects of Tagatose on Glycemic Response and Gastrointestinal Microbiota in Healthy Adults

Completed
View on ClinicalTrials.gov →
Summary
The primary objective of this clinical-trial is to determine, in subjects with impaired fasting glucose (IFG) and/or insulin resistance (IR), if tagatose meets the definition of a prebiotic, namely that consuming tagatose for 4 weeks selectively stimulates the selective growth of bacteria in the colon and is associated with a health benefit (oral glucose tolerance) when compared to consuming the control treatment (10g sucrose) for 4 weeks.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-01.
Status change: Recruiting → Completed 2026-04-16
Trial Details
NCT Number NCT06920641
Lead Sponsor PepsiCo Global R&D
Conditions Glucose Intolerance, Microbial Colonization
Enrollment 59 participants
Start Date 2025-04-10
Primary Completion 2026-01-19 (estimated)
Study Completion 2026-01-19 (estimated)
Updated on ClinicalTrials.gov 2026-04-21